Clinical Trial Update: Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Phenoptin in subjects with hyperphenylalaninemia due to tetrahydrobiopterin deficiency has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphenylalaninemia
• Tetrahydrobiopterin Deficiency

Drugs mentioned

• Phenoptin

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric | Phase 2 | Status: COMPLETED | Results posted: 2020-09-25